Pricing delay deprives Greek patients of Benlysta, Tobi, Victrelis and more
This article was originally published in Scrip
A 19-month delay in the issuance of a drug price bulletin in Greece has meant that patients with numerous severe diseases have been unable to access innovative treatments despite EU approval and their availability elsewhere in Europe.
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.